In order to search for microbial modulators of the activity of neuropeptide, we established a screen based on substance P (SP)-induced myeloperoxidase (MPO) release from human polymorphonuclear leukocytes (PMN). SP induced MPOrelease in a dose-dependent manner at concentrations ranging from 1~10x 10~4m. In comparison at 1 x 10"4m, induction was also observed with SP derivatives but not with other neuropeptides such as neurokinin and enkephalin. Based on this, we searched for microbial inhibitors against SP-induced MPOrelease. Anactinomycete metabolite designated HS3, which turned out to be identical with dioxapyrrolomycin or A1-R2081, and structurally related pyrrolomycins were found to inhibit SP-induced MPOrelease. In addition, these compounds inhibited the f-Met-Leu-Phe (FMLP)-induced MPO release from PMlfl.
Wehave been studying human polymorphonuclear leukocytes (PMN) functions. One of our major concerns is the PMNresponse to stimuli such as lung carcinoma-derived chemotaxin (LUCT/interleukin-8)1~3), inflammatory mediators and neurosubstances. Wehave thought that such PMNresponse would be useful as a screen to search for novel biologically active substances or to reveal unknownactivity of known compoundsincluding antibiotics. Eventually wewere successful to discover aseanostatins that inhibit the f-Met-Leu-Phe (FMLP)-induced myeloperoxidase (MPO) release from PMN4).
Substance P (SP) has been knownas a neuropeptide involved in inflammatory reaction5'6). Recently, it has been reported that SP induced the chemotaxis of PMN as well as the release of lysosomal /?-glucuronidase (BGL)7) and the respiratory burst8'9). In addition, the SP receptor is distributed widely among tissues10). Based on this, we thought that SP-induced MPOrelease from human PMNcould be established as a screen to search for inhibitors of SP function. If such inhibitors are available, we may improve our understanding howSP is involved in physiological events such as inflammation or on the mechanism of SP binding to its receptor. As a result of screening, an actinomycete metabolite designated HS3, which turned out to be identical with Al-2081 1 1*, LL-F4228a12) or dioxapyrrolomycin13), was found to exhibit an inhibitory effect on MPO release. In this paper, the effect of HS3 and related antibiotics (pyrrolomycins) on SP-induced MPOrelease is described.
Chemicals THE JOURNAL OF ANTIBIOTICS
Materials and Methods MAY 1991 SP, other neuropeptides (Table 1) and f-Met-Leu-Phe (FMLP) were purchased from Protein Research Foundation (Osaka, Japan). Cytochalasin B (CB) and 3, 3', 5, were obtained from Sigma Chemical Company(St. Louis, U.S.A.). TMBwas dissolved in A^JV-methylformamide (Katayama Chemical, Osaka, Japan). Pyrrolomycin and its derivatives were obtained from Meiji Seika Kaisha, Ltd. (Japan)14~18).
Preparation of PMN
PMNwere isolated from venous blood of healthy human adult volunteers on a Lymphoprepdensity as described previously19).
Assay for MPORelease
For induction of MPOrelease from PMN, the prewarmed (37°C, 10 minutes) PMNsuspension (37.5/zl; 2 x 106 cells/ml of Hank's balanced salt solution (HBSS)) was mixed with SP (7.5^1), phosphate buffered saline (PBS; 1.5fA) and HBSS (22.5^1). The mixture (75jul) was then incubated at 37°C for 10 minutes in a plastic plate with 96 wells (Nunc, Denmark). Microbial culture extracts or purified chemicals (7.5 fd) were substituted for PBS when their effect on MPOrelease was examined. After incubation, the plate was chilled on ice for 1 minute and centrifuged at 330 x g at 4°C for 5 minutes to separate supernatants from the cell. The cell pellets were then disrupted by suspending and mixing well with 150^1 of cold HBSScontaining 0. 1 %Triton X-100to obtain cell-lysates. Both the cell-lysates and the supernatants were assayed for their MPOactivity according to the method described previously20'2X). MPOactivity in the supernatants was regarded as the MPOrelease from the PMNand total MPOactivity referred to the supernatant MPOactivity+ the cell lysate MPOactivity. Percent MPOrelease was therefore calculated as 100 x supernatant MPOactivity/(supernatant+cell lysate) MPOactivity. One unit of MPOactivity was defined as the 1.0 increase in absorbance at 655 nm (103 x AA655/minute/ml of sample) due to formation of the oxidation product from tetramethylbenzidine as an appropriate substrate.
SP was dissolved in HBSS right before the assay. PBS (pH 7.3) consisted of NaCl 8.0g, KC1 0.2g, Na2HPO4 (anhydrous) 1.15g and KH2PO4 (anhydrous) 0.2g/liter of double distilled water (DDW). Des-Thr^y-endorphin 3.9 100 x supernatant/(cell lysate + supernatant).
HBSS consisted of NaCl 8.0g, KC1 0.4g, Na2HPO4 (anhydrous) 47.9mg, KH2PO4 60mg, MgSO4 (anhydrous) 48.8 mg, MgCl2 (anhydrous) 46.8mg, CaCl2 (anhydrous) 140mg and glucose 1.0 g/liter of DDW.
Preparation of Microbial Culture Extracts
Soil isolates of actinomycetes, bacteria and fungi were cultivated on a rotary shaker at 26~28°C for 3~4 days in 500-ml Erlenmeyer flasks each containing 80~100ml of the following media: Medium for actinomycetes consisted of malt syrup 3.0%, soy bean oil 0.15%, soy bean meal 1.5%, soluble vegetable protein (SVP) 0.5%, Pharmamedia 1.0%, NaNO3 0.3% and CaCO3 0.2%, pH 7.0. Medium for bacteria and fungi consisted of glucose 2.0%, starch 1.0%, soy bean meal 1.25%, wheat germ 0.8%, *NaCl 0.125% and CaCO3 0.15%, pH 7.0.
After incubation, each broth was added to an equal volume of EtOAcand mixed vigorously. The EtOAclayers were taken out and evaporated. The resultant residues were dissolved in an equal volume of PBS and diluted to 3 and 10% with PBS for the MPOrelease assay.
Purification and Characterization of HS3
A slant culture of strain HS3was inoculated into 100ml of a seed mediumin a 500-ml Erlenmeyer flask and incubated at 28°C for 2 days on a rotary shaker at 220 rpm. The seed medium consisted of starch 1.0%, glucose 1.0%, peptone 0.5%, meat extract 0.2%, yeast extract 0.3%, soy bean meal 0.2% and CaCO3 0.2%, pH 7.0. The seed culture (1.6 ml) was then transferred into twenty 500-ml Erlenmeyer flasks each containing 80ml of a production mediumand incubated for 65 hours under the same conditions as those for the seed culture. The production medium consisted of starch 2.0%, wheat germ 2.0%, SVP0.5%, NaCl 0.25%, CaCO3 0.3% and CoCl2-6H2O 0.001%. The cultured broth was mixed with EtOAc (1.0 liter) and filtered at pH 7.5 with the aid of Celite. The EtOAc layer was separated, washed with water and concentrated to dryness. The resultant residue (0.25 g) was chromatographed on a silica gel column (50 g) developed with CHCl3 -MeOH(50 : 1). The active fractions were pooled and concentrated and the resulting powder (75mg) was purified on a Sephadex LH-20 column developed with MeOH. Finally, recrystallization of the crude powder from hot benzene was carried out. The recrystallization yielded 38 mg of pale yellow crystals designated HS3.
Physico-chemical characterization of HS3 was carried out by NMR, EI-MS, IR, TLC.
Results

Effective Concentration of SP for Stimulation of MPORelease from HumanPMN
In order to establish the basis for a novel screen, we first examined the effective dose range of SP on MPOrelease from human PMN. As shown in Fig. 1 , a dose-dependent induction of MPO release was observed at concentrations ranging from 1 -10 x 10~4m. The highest effect was obtained at 10 x 10~4m. No significant induction was detected at concentrations lower than 1 x 10~4m (data not shown). It has been known that FMLP causes MPOrelease from human PMNin the presence of CB22). Therefore, CB (5 /jg/ml) was examined for its effect on the SP-induced MPOrelease (Fig. 1) . It turned out that a stimulative effect of CB was observed in the lower range of SP concentrations (l~3x 10~4m), whereas a suppressive effect of CB was observed at higher SP concentrations over 5 x 10 4 m. Extracellular levels of lactate dehydrogenase (LDH)as a cytosol enzyme of PMNwere also examined according to the method of Pesce et al.22) . The LDHlevels remained at the basal level in the presence of 5~10 x 10~4m SP (data not shown), indicating that SP did not cause the leakage of PMNcytosol.
SP derivatives and several other neuropeptides such as neurokinin and enkephalin were also examined for their capability of inducing MPOrelease at the concentration of 1 x 10~4m( Table 1) . None of the latter substances showed obvious induction, while SP derivatives clearly induced MPOrelease. The effect of SP derivatives was, however, weaker than that of SP.
Screening of Microbial Metabolites Inhibiting the SP Effect Based on the above results, weemployed1 x 10"4mofSP for the induction ofMPOrelease to screen for microbial inhibitors against the SP-dependent MPOrelease. Wehave screened EtOAcextracts of 100 actinomycete, 100 fungal and 50 bacterial cultured broths. Inhibitory activity was reproducibly observed with samples from 12 actinomycete, 3 fungal and 5 bacterial cultured broths. Total MPOactivity of PMN that referred to the combined activity of supernatant MPOand cell lysate MPOremained at a constant level (data not shown). This indicated that a low level of MPOactivity in the supernatants should not be due to the inhibition of the enzyme activity of MPObut to the inhibition of MPOrelease from PMN. Amongthe active samples, the sample derived from an actinomycete strain designated HS3with the strongest activity was chosen for further characterization because a nematoda, Caenorhabditis elegans, was also inhibited in a mannersuggesting activity on the nervous system (data not shown).
Inhibition of SP-induced MPORelease by HS3 and Pyrrolomycins An active principle designated HS3 was isolated and purified from the EtOAc extract of the cultured broth of the actinomycete strain HS3. Chemical characterization revealed that HS3 was identical with Al-R20811O) or dioxapyrrolomycin12) (Fig. 2) indicated that the chemical structure of HS3 was closely related to that of the pyrrolomycin group antibiotics. Finally, HS3 was identified as dioxapyrrolomycin (A1-R2081) on the basis of TLC, mp and IR data. Taxonomicproperties of the HS3 producer fell into those of Streptomyces (data not shown). Therefore the strain was designated as Streptomyces sp. HS3. Fig. 3 shows the inhibitory effect ofHS3 on MPOrelease induced by 7 x 10~4m SP and by a mixture of FMLP (1 x 10~~6m) and CB (5^ug/ml). While approximately 2-and 3-fold increases in MPOrelease were observed with SP and a mixture of FMLPand CB, respectively, without addition of HS3, these increases were inhibited by the addition of HS3in a dose-dependent manner. The MPOrelease induced by both SP and the mixture of FMLPand CB was inhibited almost completely by 1 jug/ml of HS3. IC50 was estimated at O.l jug/ml for the MPOrelease induced by SP and 0.3/jg/ml for that induced by the mixture of FMLPand CB. HS3 itself showed no effect on the MPOrelease from human PMN. Since HS3 turned out to be one of the pyrrolomycin group of antibiotics (Fig. 2) , we examined the inhibitory effect of these compounds at the concentrations of 0.1 /ig/ml and 10 jug/ml. As" shown in Table  2 , HS3, pyrrolomycins (A, B, C, D and Fl) and their methylated derivatives strongly inhibited SP-induced MPOrelease; 45~80% at 0.1 /zg/ml and almost completely at 10^g/ml, indicating a dosage effect. The FMLP-induced release in the presence of CB was also inhibited by these compounds except for the a In the presence of CB (5jug/ml). a 100 x (compound-basal)/(SP or FMLP-basal). In this equation , 1) methylated pyrrolomycin derivatives. Their inhibition was, however, weaker than that against the SP stimulation. Furthermore, the dosage effect of the methylated pyrrolomycins was not parallel with that of the nonmethylated pyrrolomycins. Mono-or di-methyl pyrrolomycins (10 /ig/ml) showed little or no inhibition against the FMLP-induced MPOrelease in the presence of CB selectively, while they showed high inhibition (comparable to nonmethylated ones) against the SP-induced MPOrelease.
Pyrrolnitrin, another antibiotic containing the pyrrole ring (Fig. 2) , also showed a relatively high activity against the MPOrelease induction by SP. The FMLP-induced MPOrelease was not significantly inhibited by the antibiotic. Aseanostatin P54) (12-methyltetradecanoic acid) that was recently discovered by us as an inhibitor against the FMLP-induced MPOrelease was also examined for its capability of inhibiting SP-induced MPOrelease (Table 3) of MPOrelease by the neuropeptides we examined was remarkable with only SP. Since the extracellular activity of LDH(a cytosol enzyme) of PMNinduced with SP remained at the basal level, the increase in the extracellular activity of MPOcaused by SP would not be due to leakage by membrane damage but to release by exocytosis. SP and neurokinin A are tachykinin family neuropeptides that share Phe-X-Gly-Leu-Met-NH2as the commoncarboxyl terminal sequence23'240. It is. therefore suggested that the N-terminal side sequence of SP is effective for the induction of the MPOrelease.
It will be noted that the SP derivatives we used are known as antagonists of SP25) and induced the MPOrelease from PMN. This suggests that SP antagonists can be detected by testing the increase in MPO release from PMN.Since the MPOrelease from PMNcan be easily and rapidly assayed in a small scale, the PMNresponse to exogeneous substances will be useful not only to search for novel compoundswith novel activity but also to reveal activities of known antibiotics.
Pyrrolomycin group antibiotics have so far been noted only for their antibiotic activityll~14). It was revealed in the present study that they showed a high inhibitory activity against the MPOrelease induced by either SP or FMLP.Thus unknown activities of pyrrolomycin group antibiotics was first visualized. For high activity against the FMLP-induced MPOrelease, the NHof the pyrrole ring seems to be critical, since iV-methylation of the pyrrole ring resulted in the selective reduction of their activity against FMLP-induced MPOrelease. This was paralleled with the loss of antibiotic activity of pyrrolomycins (unpublished data) and was in contrast to the result of aseanostatin P5 that did not inhibit the SP-induced MPOrelease from human PMNbut rather the FMLP-induced MPOrelease. One possibility for this differential activity between pyrrolomycins and their TV-methylated derivatives will be differential binding to the receptor(s) for SP and FMLP.It has been known that SP binds to the FMLPchemotaxis receptor on the rabbit neutrophil7). The same thing might be true for the humanneutrophil or PMN. Based on this postulation, pyrrolomycins may block binding sites for both SP and FMLPon the receptor and the Af-methylated derivatives only the SP site. However, we can not rule out that PMNhas a different receptor for SP from that for FMLP. Another possibility will be the differential activity to initiate signal transduction or exocytosis for the release of lysosomal enzymes.Comparativestudies on the modeof action of these compounds including aseanostatin4) are now in progress. SP has been knownas a neurotransmitter of pain23) and recently as a likely mediator or regulator for inflammatory reactions or immune responses5'26). In relation to SP function in the nervous system, baclofen23) (a GABAderivative) has been known as an SP antagonist whose structure is not similar to SP (Fig. 4) . Werecently noticed that this antagonist has a 4-chlorophenyl moiety that has similarity with the pyrrolomycin group antibiotics. Since GABAis not an antagonist of SP, the 4-chlorophenyl moiety will be critical for the antagonistic activity to SP of baclofen. It is therefore of interest whether pyrrolomycin group antibiotics act as antagonists of SP in the nervous system.
